Title: Cannabinoid receptor antagonist-induced striated muscle toxicity and ethylmalonic-adipic aciduria in beagle dogs.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20121001
Title: JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities.
Journal: Bioorganic & medicinal chemistry letters 20121001
Title: Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight.
Journal: Diabetes, obesity & metabolism 20120601
Title: Surface energy analysis as a tool to probe the surface energy characteristics of micronized materials--a comparison with inverse gas chromatography.
Journal: International journal of pharmaceutics 20120117
Title: Physical stability and recrystallization kinetics of amorphous ibipinabant drug product by fourier transform raman spectroscopy.
Journal: Journal of pharmaceutical sciences 20111101
Title: Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.
Journal: Bioorganic & medicinal chemistry letters 20100301
Title: Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
Journal: Bioorganic & medicinal chemistry letters 20090801
Title: Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.
Journal: Journal of medicinal chemistry 20090409
Title: Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.
Journal: Journal of medicinal chemistry 20080424
Title: Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Journal: Journal of medicinal chemistry 20080410
Title: Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole.
Journal: Bioorganic & medicinal chemistry letters 20080201
Title: Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.
Journal: Journal of medicinal chemistry 20071129
Title: Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Journal: Journal of medicinal chemistry 20061228
Title: Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.
Journal: Bioorganic & medicinal chemistry letters 20051101
Title: Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
Journal: Journal of medicinal chemistry 20040129
Title: Lange JHM, et, al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem. 2004 Jan 29;47(3):627-43.
Title: Tam J, et, al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012 Aug 8;16(2):167-79.
Title: Rohrbach K, et, al. Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. Diabetes Obes Metab. 2012 Jun;14(6):555-64.
